Sandoz Group (OTCMKTS:SDZNY) Hits New 12-Month High - Should You Buy?

Key Points

• Sandoz Group's share price reached a new 52-week high of $63.72 during mid-day trading, indicating strong market interest.
• Analysts have given a consensus rating of "Hold" on Sandoz Group, with Jefferies Financial Group recently downgrading their rating from "strong-buy" to "hold".
• The company's financial metrics show a debt-to-equity ratio of 0.57 and a current ratio of 1.24, suggesting stable liquidity and manageable debt levels.

Shares of Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report) hit a new 52-week high during trading on Friday . The stock traded as high as $63.72 and last traded at $63.72, with a volume of 369 shares. The stock had previously closed at $63.00.

Analysts Set New Price Targets

Separately, Jefferies Financial Group downgraded shares of Sandoz Group from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 8th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of "Hold".

Sandoz Group Stock Up 0.4%

The company has a quick ratio of 0.79, a current ratio of 1.24 and a debt-to-equity ratio of 0.57. The business's fifty day simple moving average is $58.15 and its 200 day simple moving average is $49.68.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.